Zealand Pharma A/S (ZEAL.CO)
| Previous Close | 727.50 |
| Open | 735.00 |
| Bid | 730.00 x 0 |
| Ask | 728.50 x 0 |
| Day's Range | 725.00 - 742.00 |
| 52 Week Range | 325.00 - 972.00 |
| Volume | |
| Avg. Volume | 247,647 |
| Market Cap | 51.572B |
| Beta (5Y Monthly) | 0.54 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -16.73 |
| Earnings Date | Nov 07, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 1,015.00 |
GlobeNewswireZealand Pharma to participate in the Jefferies London Healthcare Conference
Press Release – No. 11 / 2024 Zealand Pharma to participate in the Jefferies London Healthcare Conference Copenhagen, Denmark, November 13, 2024 – Zealand Pharma A/S (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announced that Chief Executive Officer, Adam Steensberg, will participate in a fireside chat at the Jefferies London Healthcare Conference at 9:30 a.m. GMT (10:30 a.m. CET) on Thursday, November 21, 2024. A liv
Simply Wall St.Exploring High Growth Tech Stocks In November 2024
Global markets have recently experienced significant shifts, with U.S. stocks rallying to record highs following a Republican electoral sweep, leading to expectations of accelerated earnings growth and reduced regulatory burdens. Amidst these developments, the small-cap Russell 2000 Index has shown impressive gains, highlighting the potential opportunities within high-growth tech stocks as investors seek companies that can thrive under favorable economic policies and lower corporate taxes.
